scholarly journals Pathogenic Role of Modified LDL Antibodies and Immune Complexes in Atherosclerosis

2013 ◽  
Vol 20 (10) ◽  
pp. 743-754 ◽  
Author(s):  
Maria F. Lopes-Virella ◽  
Gabriel Virella
2000 ◽  
Vol 74 (9) ◽  
pp. 4116-4126 ◽  
Author(s):  
Nobutada Tabata ◽  
Masaaki Miyazawa ◽  
Ryuichi Fujisawa ◽  
Yumiko A. Takei ◽  
Hiroyuki Abe ◽  
...  

ABSTRACT Several strains of mice, including MRL/MpJ mice homozygous for the Fas mutant lpr gene (MRL/lpr mice), F1 hybrids of New Zealand Black and New Zealand White mice, and BXSB/MpJ mice carrying a Y-linked autoimmune acceleration gene, spontaneously develop immune complex-mediated glomerulonephritis. The involvement of the envelope glycoprotein gp70 of an endogenous xenotropic virus in the formation of circulating immune complexes and their deposition in the glomerular lesions have been demonstrated, as has the pathogenicity of various antinuclear, antiphospholipid, and rheumatoid factor autoantibodies. In recent genetic linkage studies as well as in a study of cytokine-induced protection against nephritis development, the strongest association of serum levels of gp70–anti-gp70 immune complexes, rather than the levels of antinuclear autoantibodies, with the development and severity of glomerulonephritis has been demonstrated, suggesting a major pathogenic role of anti-gp70 autoantibodies in the lupus-prone mice. However, the pathogenicity of anti-gp70 autoantibodies has not yet been directly tested. To examine if anti-gp70 autoantibodies induce glomerular pathology, we established from unmanipulated MRL/lpr mice hybridoma clones that secrete monoclonal antibodies reactive with endogenous xenotropic viralenv gene products. Upon transplantation, a high proportion of these anti-gp70 antibody-producing hybridoma clones induced in syngeneic non-autoimmune and severe combined immunodeficiency mice proliferative or wire loop-like glomerular lesions. Furthermore, deposition of gp70 in glomeruli and pathological changes were observed after intravenous injection of representative clones of purified anti-gp70 immunoglobulin G, demonstrating pathogenicity of at least some anti-gp70 autoantibodies.


2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 180.2-180
Author(s):  
C.B. Chighizola ◽  
E. Raschi ◽  
L. Cesana ◽  
M.O. Borghi ◽  
P.L. Meroni

2020 ◽  
Vol 217 ◽  
pp. 108493 ◽  
Author(s):  
Dominique A. Vuitton ◽  
Lucine Vuitton ◽  
Estelle Seillès ◽  
Pierre Galanaud

2019 ◽  
Vol 20 (14) ◽  
pp. 3561 ◽  
Author(s):  
Summerhill ◽  
Grechko ◽  
Yet ◽  
Sobenin ◽  
Orekhov

Lipid accumulation in the arterial wall is a crucial event in the development of atherosclerotic lesions. Circulating low-density lipoprotein (LDL) is the major source of lipids that accumulate in the atherosclerotic plaques. It was discovered that not all LDL is atherogenic. In the blood plasma of atherosclerotic patients, LDL particles are the subject of multiple enzymatic and non-enzymatic modifications that determine their atherogenicity. Desialylation is the primary and the most important atherogenic LDL modification followed by a cascade of other modifications that also increase blood atherogenicity. The enzyme trans-sialidase is responsible for the desialylation of LDL, therefore, its activity plays an important role in atherosclerosis development. Moreover, circulating modified LDL is associated with immune complexes that also have a strong atherogenic potential. Moreover, it was shown that antibodies to modified LDL are also atherogenic. The properties of modified LDL were described, and the strong evidence indicating that it is capable of inducing intracellular accumulation of lipids was presented. The accumulated evidence indicated that the molecular properties of modified LDL, including LDL-containing immune complexes can serve as the prognostic/diagnostic biomarkers and molecular targets for the development of anti-atherosclerotic drugs.


2017 ◽  
pp. 66-71
Author(s):  
O. Yablon ◽  
◽  
N. Zaichko ◽  
O. Mazulov ◽  
Z.I. Rossokha ◽  
...  

10.2741/2875 ◽  
2008 ◽  
Vol 13 (13) ◽  
pp. 2686 ◽  
Author(s):  
Toshiyuki Yamamoto
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document